Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Nanobiotix, which saw its stock soar after reporting phase 2/3 soft tissue sarcoma data. Novo Holdings invested CHF 20 million ($20 million) in NBE Therapeutics. Boehringer Ingelheim unveiled a €230 million investment in a German biologics center. Summit Therapeutics dumped its Duchenne muscular dystrophy drug following a midphase failure. The EMA told Amicus Therapeutics to generate more data before filing for conditional approval. And more.—Nick Taylor
A phase 2/3 trial of Nanobiotix’s NBTXR3 in soft tissue sarcoma has met (PDF) its primary endpoint. The top-line success against the pathological complete response rate endpoint sent Nanobiotix’s stock up by more than 50%.
Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.
Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity. The investment will support the construction of a biologics development center at Boehringer's R&D site in Biberach, Germany.
Despite putting up encouraging early data, Summit Therapeutics' Duchenne muscular dystrophy (DMD) drug missed its primary and secondary endpoints in a phase 2 trial, leading the biotech to drop the program and focus its energies behind its antibiotic pipeline.
The EMA has told Amicus Therapeutics it lacks the data to file for conditional approval of its Pompe disease drug in Europe. Amicus needs to gather data on more patients and track the progress of previously treated people before seeking conditional approval, delaying the filing to 2019 or beyond.